Clinical Trial Update: High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating high-dose ald( e)leukin and ipilimumab in unresectable stage III-IV melanoma; the study is terminated but results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Aldesleukin (interleukin-2)
• ipilimumab (ipilimumab)

Snippet

Sponsor: CINJRegulatory | Conditions: Recurrent Melanoma, Stage IIIA Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2023-06-18